Literature DB >> 25797707

IgG4-related disease, retrospective histopathological diagnosis. Prevalence in a University Hospital.

David Alejandro Herrera van Oostdam1, Tonatiu Jaimes Piñón1, Marco Ulises Martínez-Martínez1, Cuahutémoc Oros-Ovalle1, Natalia Aléman-Sánchez1, Carlos Abud-Mendoza2.   

Abstract

INTRODUCTION: IgG4 related diseases (IgG4-RD) are characterized mainly by organic dysfunction and inflammation with lymphoplasmacytic cells infiltration.
METHODS: We conducted a retrospective study. We analyzed patients with a diagnosis of IgG4-RD through histopathologic registries. We divided the study into three phases: (i)extraction of data from the registries of the Pathology Department, including specimens reported with: non-specific inflammation with plasmatic cell infiltration, inflammatory pseudo-tumors and storiform fibrosis, and excluding any report of cancer or infection; (ii)from the selected specimens, three pathologists microscopically re-analyzed these biopsies and included only those who had at least two of the inclusion criteria cited above; (iii)finally, immunostaining was performed in the specimens selected in the second phase. The selected biopsies were catalogued as compatible for IgG4-RD if they had at least 3 inclusion criteria and as probable if they had 2 inclusion criteria.
RESULTS: On the first phase of the study we analyzed 23,720 biopsies, from which we included 71 and excluded 29 specimens; the rest of the specimens (n=41) underwent immunostaining. From the biopsies included, 41.4% (n=17/71) were positive to IgG4, with the most common histological diagnosis for the positive specimens being granulomatous mastitis, which represented 12.1% of the specimens catalogued initially as probable. The rest of the positive biopsies were from aortitis, dacrioadenitis and/or sialoadenitis, lung pseudo-inflammatory tumor, pericarditis and chronic pancreatitis.
CONCLUSIONS: The suspicion of IgG4 related disease should not be based solely on clinical manifestations or serology. In the present study we confirm the characteristic changes of IgG4-RD in patients without initial clinical suspicion.
Copyright © 2014 Elsevier España, S.L.U. y Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.

Entities:  

Keywords:  Chronic sialoadenitis; Enfermedades relacionadas con IgG4; Granulomatous mastitis; IgG4 related disease; Inflammatory tumor; Mastitis granulomatosa; Sialodenitis crónica; Tumor inflamatorio

Mesh:

Substances:

Year:  2015        PMID: 25797707     DOI: 10.1016/j.reuma.2014.12.007

Source DB:  PubMed          Journal:  Reumatol Clin        ISSN: 1699-258X


  4 in total

1.  The many faces of IgG4-related disease: report of a case with inaugural recurrent aortic aneurism ruptures and literature review.

Authors:  Mariana Luís; Luísa Brites; Bruno Fernandes; Diogo Jesus; Tânia Santiago; Sara Serra; João Rovisco; Lina Carvalho; José António P da Silva; Armando Malcata
Journal:  Rheumatol Int       Date:  2018-05-12       Impact factor: 2.631

2.  Mastitis associated with Sjögren's syndrome: a series of nine cases.

Authors:  Radjiv Goulabchand; Assia Hafidi; Ingrid Millet; Jacques Morel; Cédric Lukas; Sébastien Humbert; Sophie Rivière; Christian Gény; Christian Jorgensen; Alain Le Quellec; Hélène Perrochia; Philippe Guilpain
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

3.  Immunoglobulin G4-related gastric pseudotumor - An impostor: Case report.

Authors:  Manuel Santiago Mosquera; Andrea Suarez Gómez; Hugo Herrera; Karen Moreno-Medina; Alejandro González-Orozco; Carlos J-Perez Rivera
Journal:  Int J Surg Case Rep       Date:  2020-09-10

Review 4.  Mastitis in Autoimmune Diseases: Review of the Literature, Diagnostic Pathway, and Pathophysiological Key Players.

Authors:  Radjiv Goulabchand; Assia Hafidi; Philippe Van de Perre; Ingrid Millet; Alexandre Thibault Jacques Maria; Jacques Morel; Alain Le Quellec; Hélène Perrochia; Philippe Guilpain
Journal:  J Clin Med       Date:  2020-03-30       Impact factor: 4.964

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.